Today: 3 May 2026
Browse Category

NASDAQ:AGIO 19 November 2025

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals’ Phase 3 RISE UP trial of mitapivat in sickle cell disease met its hemoglobin-response primary endpoint but failed to show a significant reduction in pain crises or fatigue. Shares fell sharply, dropping as much as 50% pre-market before paring losses. The company plans to meet with the FDA in early 2026 to discuss a potential U.S. marketing application.
19 November 2025
··

Stock Market Today

  • TFI International Shares Soar 43% in April Amid Analyst Target Upgrades
    May 3, 2026, 11:23 AM EDT. Quebec-based TFI International Inc. (TFII:TSX) surged 43% since late March after beating earnings estimates and raising second-quarter guidance. Major banks, including Bank of America, Citigroup and TD Cowen, raised price targets, citing strong momentum and a robust balance sheet. TD Cowen's Jason Seidl increased the target to $209 from $177, pointing to an 'unwarranted' discount compared to peers. CIBC Capital Markets bumped its target to $221 from $185. The stock rebounded sharply after last year's selloff linked to a reversed U.S. headquarters move, up 85% since then. The current 12-month average target stands at $207.75 based on 18 analysts' calls.

Latest article

Cameco Corporation Earnings Countdown: The Uranium Stock Test Investors Are Watching

Cameco Corporation Earnings Countdown: The Uranium Stock Test Investors Are Watching

3 May 2026
Cameco shares closed lower Friday, with NYSE-listed CCJ at $120.60 and TSX-listed CCO at C$163.66. The uranium supplier reports first-quarter results before markets open May 5, followed by an executive call at 8 a.m. Eastern. Investors are watching uranium prices, delivery timing, and Cameco’s 49% stake in Westinghouse. The company’s annual meeting is set for May 7.
Everspin Stock Jumps After $40 Million Defense MRAM Deal — Why Investors Are Watching Now

Everspin Stock Jumps After $40 Million Defense MRAM Deal — Why Investors Are Watching Now

3 May 2026
Everspin Technologies shares jumped $3.19 to $21.49 after announcing a $40 million U.S. defense MRAM subcontract with Amentum Services, set to run through November 2028. First-quarter revenue rose to $14.9 million, with MRAM product sales at $14.1 million. The company posted a GAAP net loss of $0.3 million. Second-quarter revenue is forecast at $15.5 million to $16.5 million.
Why ON Semiconductor’s $103 Stock Faces a Hard Earnings Test on Monday

Why ON Semiconductor’s $103 Stock Faces a Hard Earnings Test on Monday

3 May 2026
ON Semiconductor will report first-quarter earnings after markets close Monday, with analysts expecting 61 cents per share on $1.49 billion in revenue. Shares closed at $103.03 Friday, up 2.2%, far above the average analyst target of $67.15. Investors are focused on signs of recovery in auto and industrial chip demand. The company’s market value stands at about $42 billion.
Go toTop